Avalo Therapeutics (AVTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

Avalo Therapeutics Revenue Highlights

Latest Revenue (Y)

$441.00K

Main Segment (Y)

Product

Avalo Therapeutics Revenue by Period

Avalo Therapeutics Revenue by Year

Date	Revenue	Change
2024-12-31	$441.00K	-77.08%
2023-12-31	$1.92M	-89.34%
2022-12-31	$18.05M	234.40%
2021-12-31	$5.40M	-19.42%
2020-12-31	$6.70M	-0.76%
2019-12-31	$6.75M	-63.17%
2018-12-31	$18.33M	-34.11%
2017-12-31	$27.81M	2312.24%
2016-12-31	$1.15M	100.00%
2015-12-31	-	100.00%
2014-12-31	-	100.00%
2013-12-31	-	-100.00%
2012-12-31	$82.76K	-

Avalo Therapeutics generated $441.00K in revenue during NA 2024, up -77.08% compared to the previous quarter, and up 6.53% compared to the same period a year ago.

Avalo Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-09-30	-	100.00%
2025-06-30	-	100.00%
2025-03-31	-	-100.00%
2024-12-31	$192.00K	-22.89%
2024-09-30	$249.00K	100.00%
2024-06-30	-	100.00%
2024-03-31	-	-100.00%
2023-12-31	$571.00K	141.95%
2023-09-30	$236.00K	-63.30%
2023-06-30	$643.00K	35.37%
2023-03-31	$475.00K	-46.99%
2022-12-31	$896.00K	-94.01%
2022-09-30	$14.95M	1347.14%
2022-06-30	$1.03M	-11.94%
2022-03-31	$1.17M	435.62%
2021-12-31	$219.00K	-83.78%
2021-09-30	$1.35M	-59.76%
2021-06-30	$3.35M	609.30%
2021-03-31	$473.00K	-68.39%
2020-12-31	$1.50M	34.70%
2020-09-30	$1.11M	-16.97%
2020-06-30	$1.34M	-51.42%
2020-03-31	$2.75M	-131.57%
2019-12-31	$-8.72M	-255.41%
2019-09-30	$5.61M	26.16%
2019-06-30	$4.45M	-17.78%
2019-03-31	$5.41M	8.57%
2018-12-31	$4.98M	22.32%
2018-09-30	$4.07M	-14.84%
2018-06-30	$4.79M	6.74%
2018-03-31	$4.48M	100.70%
2017-12-31	$2.23M	-91.08%
2017-09-30	$25.04M	15766.66%
2017-06-30	$157.80K	-58.93%
2017-03-31	$384.21K	111.10%
2016-12-31	$182.00K	-43.39%
2016-09-30	$321.50K	-50.58%
2016-06-30	$650.49K	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	-

Avalo Therapeutics generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Avalo Therapeutics Revenue Breakdown

Avalo Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Product	$441.00K	$1.41M	$3.36M	$4.77M	$6.70M
License	-	$516.00K	$14.69M	$625.00K	-

Avalo Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Sep 19	Jun 19	Mar 19	Dec 18
Product	$192.00K	$249.00K	$54.00K	$236.00K	$643.00K	$475.00K	$726.00K	$432.00K	$1.03M	$1.17M	$219.00K	$1.35M	$2.73M	$473.00K	$1.50M	$1.11M	-	-	-	-
License	-	-	-	-	$170.00K	$14.52M	-	-	-	$625.00K	-	$100.00K	-	-	-	-	-	-	-	-
Prescribed Dietary Supplements	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.32M	$1.80M	$1.79M	$1.91M
Prescription Drugs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.19M	$2.65M	$3.62M	$2.91M
Sales Force Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$159.18K
Sales Revenue, Product	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$5.51M	$4.45M	$5.41M	$4.82M

Avalo Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).

Avalo Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
CHRS	Coherus Oncology	$266.96M	$11.57M
ENTA	Enanta Pharmaceuticals	$65.32M	$18.31M
IVA	Inventiva	$17.48M	$2.73M
OBIO	Orchestra BioMed	$2.64M	$861.00K
AVTX	Avalo Therapeutics	$441.00K	-
BDTX	Black Diamond Therapeutics	-	-
AARD	Aardvark Therapeutics	-	-
EPRX	Eupraxia Pharmaceuticals	-	-
PRLD	Prelude Therapeutics	-	$6.50M
CRBU	Caribou Biosciences	-	-
TNYA	Tenaya Therapeutics	-	-

AVTX Revenue FAQ

What is Avalo Therapeutics’s yearly revenue?

Avalo Therapeutics's yearly revenue for 2024 was $441K, representing a decrease of -77.08% compared to 2023. The company's yearly revenue for 2023 was $1.92M, representing a decrease of -89.34% compared to 2022. AVTX's yearly revenue for 2022 was $18.05M, representing an increase of 234.40% compared to 2021.

What is Avalo Therapeutics’s quarterly revenue?

Avalo Therapeutics's quarterly revenue for Q3 2025 was $0, a 100.00% increase from the previous quarter (Q2 2025), and a -100.00% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $0, a 100.00% increase from the previous quarter (Q1 2025), and a 0% increase year-over-year (Q2 2024). AVTX's quarterly revenue for Q1 2025 was $0, a -100.00% decrease from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Avalo Therapeutics’s revenue growth rate?

Avalo Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -97.56%, and for the last 5 years (2020-2024) was -93.42%.

What are Avalo Therapeutics’s revenue streams?

Avalo Therapeutics's revenue streams in c 24 are Product

What is Avalo Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Avalo Therapeutics was Product. This segment made a revenue of $441K, representing 100.00% of the company's total revenue.